2 results
Approved WMOCompleted
To compare the effect of paclitaxel plus MORAb-003 to paclitaxel plus placebo on progression free survival (PFS) as determined by RECIST in subjects who are in a first platinum-resistant or refractory relapse of ovarian cancer.
Approved WMOCompleted
The primary objective of this study is to evaluate the target engagement of AZD4831, MPO inhibitor by measuring MPO specific activity in plasma following ex vivo stimulation of fresh blood samples with zymosan, in patients with HFpEF. MPO is known…